Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains
clinically challenging. Here, we harnessed circulating tumor DNA (ctDNA) to study tumor …

Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …

Background Metastatic prostate cancer is a clonally heterogeneous disease state
characterized by progressive somatic perturbations. The aim of this study was to identify cell …

PURPOSE Despite decreased screening-based detection of clinically insignificant tumors,
most diagnosed prostate cancers are still indolent, indicating a need for better strategies for …

Annotation of prostate cancer genomes provides a foundation for discoveries that can
impact disease understanding and treatment. Concordant assessment of DNA copy number …

Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations
compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent …

Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to
improve diagnosis and risk stratification. Here, we investigated the biomarker potential in …

No consensus strategies exist for prognosticating metastatic castration-resistant prostate
cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

The progression of organ-confined prostate cancer to metastatic cancer is inevitably fatal.
Consequently, identification of structural changes in the genome and associated …